Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 2
1954 1
1957 1
1970 2
1973 2
1974 3
1975 1
1978 1
1982 1
1983 2
1984 1
1985 1
1986 1
1987 1
1988 3
1989 4
1991 3
1992 2
1994 4
1995 4
1996 10
1997 7
1998 11
1999 8
2000 9
2001 17
2002 13
2003 18
2004 12
2005 25
2006 31
2007 31
2008 33
2009 38
2010 66
2011 55
2012 55
2013 50
2014 52
2015 43
2016 42
2017 58
2018 55
2019 62
2020 70
2021 77
2022 69
2023 68
2024 68
2025 63

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,099 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Li BT, et al. Among authors: de miguel m. Lancet Oncol. 2024 Jun;25(6):707-719. doi: 10.1016/S1470-2045(24)00140-2. Epub 2024 May 3. Lancet Oncol. 2024. PMID: 38710187 Clinical Trial.
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF, D'Souza A, Bello Roufai D, Tinker AV, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko ME, Oaknin A, Spanggaard I, Shapiro GI, ElNaggar AC, Panni S, Ravichandran V, Frazier AL, DiPrimeo D, Eli LD, Solit DB. Friedman CF, et al. Among authors: de miguel m. Gynecol Oncol. 2024 Feb;181:162-169. doi: 10.1016/j.ygyno.2023.12.004. Epub 2024 Jan 11. Gynecol Oncol. 2024. PMID: 38211393 Free PMC article. Clinical Trial.
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P. Rannikko JH, et al. Among authors: de miguel m. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. Cell Rep Med. 2023. PMID: 38056464 Free PMC article. Clinical Trial.
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, de Miguel MJ, Helissey C, Shu CA, Spira AI, Tomasini P, Yang JC, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Besse B, et al. Among authors: de miguel mj. J Thorac Oncol. 2025 May;20(5):651-664. doi: 10.1016/j.jtho.2024.12.029. Epub 2025 Jan 2. J Thorac Oncol. 2025. PMID: 39755170 Free article. Clinical Trial.
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Martín M, De Miguel MJ, Yu EY, Williams A, Gion M, Tan AR, Agrawal L, Rutten A, Machiels JP, Cresta S, Debruyne PR, Hennequin A, Moreno V, Minchom A, Valdes-Albini F, Petrylak D, Li L, Tsuchihashi Z, Suto F, Cheng FC, Kandil M, Barrios D, Hurvitz S. Hamilton E, et al. Among authors: de miguel mj. Clin Cancer Res. 2024 Dec 16;30(24):5548-5558. doi: 10.1158/1078-0432.CCR-24-1513. Clin Cancer Res. 2024. PMID: 39405343 Free PMC article. Clinical Trial.
The future of oncology therapeutics.
Mansinho A, Boni V, de Miguel M, Calvo E. Mansinho A, et al. Among authors: de miguel m. Expert Rev Anticancer Ther. 2017 Jul;17(7):563-565. doi: 10.1080/14737140.2017.1331131. Epub 2017 May 22. Expert Rev Anticancer Ther. 2017. PMID: 28504011 No abstract available.
Corneal stroma regeneration: Preclinical studies.
Alió Del Barrio JL, Arnalich-Montiel F, De Miguel MP, El Zarif M, Alió JL. Alió Del Barrio JL, et al. Among authors: de miguel mp. Exp Eye Res. 2021 Jan;202:108314. doi: 10.1016/j.exer.2020.108314. Epub 2020 Oct 24. Exp Eye Res. 2021. PMID: 33164825 Review.
Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M, Calvo E. de Miguel M, et al. Cancer Cell. 2020 Sep 14;38(3):326-333. doi: 10.1016/j.ccell.2020.07.004. Epub 2020 Aug 3. Cancer Cell. 2020. PMID: 32750319 Free article. Review.
T-cell-engaging Therapy for Solid Tumors.
de Miguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E. de Miguel M, et al. Clin Cancer Res. 2021 Mar 15;27(6):1595-1603. doi: 10.1158/1078-0432.CCR-20-2448. Epub 2020 Oct 20. Clin Cancer Res. 2021. PMID: 33082210 Review.
Coenzyme q10 therapy.
Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, Fernández Vega A, de la Mata M, Delgado Pavón A, de Miguel M, Pérez Calero C, Villanueva Paz M, Cotán D, Sánchez-Alcázar JA. Garrido-Maraver J, et al. Among authors: de miguel m. Mol Syndromol. 2014 Jul;5(3-4):187-97. doi: 10.1159/000360101. Mol Syndromol. 2014. PMID: 25126052 Free PMC article.
1,099 results